The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine.
Category Archives: AZBio News
Castle Biosciences to Acquire AltheaDx
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental healthContinue reading
Booth Udall Fuller Offer Intellectual Property Office Hours for AZBio Members
In partnership with Arizona BioIndustry Association (AZBio), Booth Udall are offering weekly office hours to give AZBio members the opportunity to ask questions about the protection of their intellectual property assets and general considerations for their IP strategy.
Valley Fever Collaborative – Creating Defenses Against Disease
The Valley Fever Collaborative is an initiative that supports a collaborative effort between Arizona’s three state universities focused on the development of precision medicine approaches, drug development and environmental risk abatement to reduce the financial cost and human burden of Valley Fever.
Get Engaged In the SBIR STTR Reauthorization Discussion
The SBIR/STTR Programs are currently set to expire on September 30, 2022. It would be damaging to American innovation and competitiveness if these programs were to expire before a full reauthorization can be passed. The SBIR/STTR Programs enable small businesses to develop and commercialize new innovative technologies and have a proven track record of promoting competition through a merit-based application process. Since their establishment in 1982, these programs have provided over 179,000 awards, totaling more than $54.3 billion, to U.S. small businesses. A study by the National Academy of Sciences found a commercialization rate of 50-60% for SBIR/STTR investments. You can see the impact of SBIR/STTR in Arizona by clicking here.
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
- FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2
- Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited treatment options
- FDA approval was based on pivotal Phase III VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of overall survival and radiographic progression free survival were met1
- Novartis is committed to reimagining medicine in prostate cancer with targeted radioligand therapy – a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle)
- Two pivotal Phase III studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, with a goal to move into earlier stages of disease
HTG Releases Proof-of-Approach Whitepaper Establishing Utility of Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., March 31, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”), establishing the utility of its novel approach to drug discovery utilizing its proprietary platform.Continue reading
Third Cohort of Mayo Clinic and Arizona State University MedTech Accelerator Commences
TEMPE, Ariz. — More than two years into a global pandemic, the clear need for innovative medical breakthroughs has never been more obvious. The Mayo Clinic and Arizona State University (ASU) MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, was designed to help empower medical startups to better navigate challenges while bringing forth life-changing health innovations. The third cohort of this program launched on March 28.Continue reading
HB2039 Health; Innovation; Trust Fund
On March 29, 2022, Arizona’s Senate Appropriations Committee voted unanimously to give a Do Pass as Amended recommendation for HB2039. The next step in the process is review by the Senate Rules Committee.
If HB2039 successfully completes the legislative process and is signed into law by the Governor, it will establish the statutory framework for the Arizona Health Innovation Trust Fund within the Arizona State Treasurer’s Office with the State Treasurer as Trustee. Continue reading
Making Our Way to Top-10 Bioscience Status
Arizona is not a top-10 bioscience state yet but were making the right moves and pursuing the goal. Check out some of the key programs and initiatives that will get us there.Continue reading